ObsEva (OBSV) Competitors

ObsEva (NASDAQ:OBSV) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.

Is OBSV or RNAZ more profitable?

ObsEva's return on equity of -416.36% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
TransCode Therapeutics	N/A	-934.78%	-276.08%

Does the MarketBeat Community prefer OBSV or RNAZ?

ObsEva received 313 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 85.71% of users gave TransCode Therapeutics an outperform vote while only 53.89% of users gave ObsEva an outperform vote.

Company	Underperform	Outperform
ObsEva	Outperform Votes 319 53.89%	Underperform Votes 273 46.11%
TransCode Therapeutics	Outperform Votes 6 85.71%	Underperform Votes 1 14.29%

Do insiders and institutionals have more ownership in OBSV or RNAZ?

17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 1.5% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts prefer OBSV or RNAZ?

TransCode Therapeutics has a consensus price target of $480.00, indicating a potential upside of 95,517.53%. Given TransCode Therapeutics' higher possible upside, analysts plainly believe TransCode Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
TransCode Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor OBSV or RNAZ?

In the previous week, TransCode Therapeutics had 3 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for TransCode Therapeutics and 1 mentions for ObsEva. TransCode Therapeutics' average media sentiment score of 0.16 beat ObsEva's score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ObsEva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransCode Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, OBSV or RNAZ?

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500.

Which has stronger valuation & earnings, OBSV or RNAZ?

TransCode Therapeutics has lower revenue, but higher earnings than ObsEva. ObsEva is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	$20.11M	0.02	-$58.38M	-$0.92	-0.01
TransCode Therapeutics	N/A	N/A	-$18.55M	-$774.80	0.00

Summary

ObsEva beats TransCode Therapeutics on 8 of the 15 factors compared between the two stocks.